Initiation Of Phase I/IIA Stu

RNS Number : 1612M

Immupharma PLC

19 May 2010

 



FOR IMMEDIATE RELEASE                                                                                                                                                       19 May 2010

IMMUPHARMA RECEIVES APPROVAL FOR

 INITIATION OF PHASE I/IIA STUDIES IN CANCER

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that it received an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of  IPP-204106, its anti-cancer compound with a novel and promising mechanism of action.  The first patients are expected to be dosed within the next few weeks. 

Dr Robert Zimmer, President and Chief Scientific Officer, said:  "We are delighted with the approval of our IND application, and are excited to begin Phase I in patients for IPP-204106 in the next few weeks.  Importantly, our strong financial position means we are well-placed to take the development programme forward."

For further information please contact:

ImmuPharma PLC

Robert Zimmer, President & Chief Scientific Officer                      [phone]

Richard Warr, Chairman                                                                    [phone]
Dimitri Dimitriou, Chief Executive Officer                                       [phone]

Buchanan Communications                                                           + 44 20 7466 5000

Lisa Baderoon
Catherine Breen

George Prassas

Panmure Gordon & Co                                                                    [phone]

Andrew Burnett

Rakesh Sharma

Execution Noble & Co

James Bromhead                                                                                [phone] 

 

END

 

 

MSCMMGMKMRLGGZZ